Effect of neuroleptic treatment on polysomnographic measures in schizophrenia by Taylor, Stephan F. et al.
904 BIOL PSYCHIATRY 
1991;30:904-912 
Effect of Neuroleptic Treatment on 
Polysomnographic Measures in 
Schizophrenia 
Stephan F. Taylor, Rajiv Tandon, James E. Shipley, and 
Alan S. Eiser 
To study the effects of neuroleptic therapy on sleep EEG variables in schizophrenia, as 
well as the clinical correlates of these variables, we performed polysomnographic (PSG) 
studies on 14 schizophrenic inpatients before and during neuroleptic therapy. Sleep 
continuity measures improved after 3 weeks of neuroleptic therapy, showing decreased 
sleep latency and improved sleep efficiency. REM latency increased with treatment, 
although half the patients continued to exhibit REM latencies less than 60 rain. Other 
sleep stages and measures of REM sleep (den.~'ity, activity, number of periods) did not 
appear to change with neuroleptic treatment. At baseline, REM latent3' had strong 
negative correlations with BPRS and SANS scores, but with 3 weeks of such treatment, 
this association disappeared. Further work is needed to distinguish direct medication 
effects from the effects of the changing clinical state on PSG measures. 
Introduction 
Polysomnographic (PSG) studies of schizophrenic patients have revealed a number of 
abnormalities, including reduced total sleep time and sleep continuity, reduced slow- 
wave sleep, and shortened REM latency (for a recent review, see Keshavan et al 1990). 
However, the significance of these findings remains unclear. 
One of the questions only partially addressed in the literature is how PSG findings 
change with treatment and phase of the illness. In a longitudinal study of 4-8 months 
duration of six schizophrenics (three on medication), Kupfer et al (1970) found that sleep 
abnormalities tended to occur during psychotic exacerbations and returned to near nonnal 
values as the psychotic state remitted. In investigations that have examined the effects 
of aeuroleptics at dosages and durations that would be used in clinical practice, sleep 
continuity measures showed consistent improvement, as reflected by reduced sleep latency 
(Kaplan et al 1974), improved total sleep time (Jus et al 1968; Kaplan et ai 1974; Gillin 
et aJ 1978; Keshavan et al 1989), ~reater sleep efficiency (Gillin et al 1977; Keshavan 
et al 1989), or fewer awakenings tltil et al 1971a, 1971b). 
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Changes in sleep architecture exhibit less consistency, and differing nomenclature 
describing sleep staging make interpretation of the varying results difficult. Kaplan et al 
(1974) demonstrated a slight increase in the percentage of delta sleep in patients given 
chlorpromazine, while others report a decrease in some deep stages of sleep on haloperidol 
(Keshavan et al 1989; liil et al 1970) or high-dose fluphenazine (ltil et al 1971b). Other 
studies have found no differences (Giilin et al 1978; Jus et al 1968). 
Alzerations in the onset and character of REM sleep have been noted in schizophrenia 
and provide possible clues to pathophysiological mechanisms (Keshavan et al 1990; 
Kupfer and Ehiers 1989; Tandon et al 1991). It is therefore of some intere,:t to learn how 
neuroleptic therapy alters REM. Kaplan et al (1974) have been the only group to report 
any change, which was a prolongation, of the onset of the first REM period, with 
chlorpromazine treatment. This study also found an increase in total REM activity and 
density, but not REM time. Some reports note increased REM density in schizophrenics 
treated with various neuroleptics (Jtzs et al 1968), but other investigators examining REM 
parameters have not found changes in REM activity or density after treatment with 
pimozide (Gillin et al 1978), thiothixene (ltil et al 197 la), fluphenazine (Itil et al 1971b) 
or haloperidol (Itil et al 1970). One recent report found decreased REM density after 
treatment with haioperidol (Keshavan et al 1989). The different pharmacological profiles 
of these various neuroleptics and the preliminary nature of the work prevents one from 
drawing definite conclusions about the effect of neuroleptics on REM sleep. 
We undertook the following sleep EEG study of schizophrenic patients, both before 
and after treatment with reurt~leptics, to understand how PSG and clinical variables change 
with neuroleptic treatment. In order to further address pathophysiology, w,- als~ examined 
correlations between the.,;e clinical and physiological variables. 
M e t h o d s  
We recruited 14 patients from our inpatient unit who met both DSM-III-R and SADS/RDC 
criteria for schizophrenia. The current study represents a subset of a larger group of 
schizophrenic patients studied with sleep EEG while not receiving medication (Tandon 
et ai 1991). An experienced research nurse administered the SADS. Patients who had a 
history of drug or alcohol abuse in the past 6 months or significant medical or neurological 
problems, including historical or clinical evidence of narcolepsy, were excluded from the 
study. Eligible patients gave informed consent before participating in the study. 
Demographic characteristics of the 14 patients are listed in Table 1. Their average age 
was 31. I years and their average duration of illness was 7.7 years. Six patients had never 
received neuroleptic medication previous ;o this study. Patients who had been receiving 
neuroleptic medication did not receive any psychotropic medication for a minimum of 2 
weeks before the first night of sleep recordings. 
In the drug-free state and at the time of the first PSG recording, the patients underwent 
clinical ratings by means of the 18-item Brief Psychiatric Rating Scale (BPRS) (Overall 
and Gorham 1962), and the Scale for the Assessment of Negative symptoms (SANS) 
(Andreasen 1983). After completion of the pret~eatment PSG, neuroleptic therapy was 
begun with either haloperidol or thiothixene at clinically indicated doses (Table 1). Ten 
patients required treatmer, t with antiParkinsonian medication (either benztropine or tri- 
hexyphenydil) for extrapyramidal symptoms. After an average of 24.4 days of neuroleptic 
treatment, the patients underwent two more nights of sleep EEG monitoring and the 
clinical ratings were repeated, in addition to the rating scales described, we also derived 
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Tablc i. Patient Characteristics and Treatment Data 
Chlorpromazine Benztropine 
Dose--- Dose- -  
DSM-IlI-R Duration Equivalent Equivalent Trea'~ment 
Subtype Age Sex Education I!I (yr) Medication (rag/day) (mg/day) Days 
I Undifferentiated 34 M 13 13 Thiothixene 500 2 22 
2 Paranoid 34 M !2 17 Haloperidol 750 4 44 
3 Paranoid 28 M 12 7 Thiolhixene 800 6 22 
Undifferentiated 23 F 12 1.2 Thiothixene 600 3 23 
5 Undifferentiated 44 F 12 4 Halopendol 1650 0 20 
6 Undifferentiated 22 M 12 1.5 Thiothixenc 600 I ~.2 
7 Paranoid 29 F 17 l Thio~hixene 300 2 19 
8 Paranoid 43 M 15 0.5 Thiothixene 400 I 29 
9 Para~.ioid 27 M 14 14 Thiothixene 400 2 27 
l0 Undifferenliated 33 M 15 l0 Thiothixene 600 I 14 
I I Disorganized 20 M 12 0.5 Haloperidol 495 0 19 
12 Paranoid 45 M 14 24 Haloperidol 660 0 27 
13 Undifferentiated 29 M 12 14 Haloperidol 1000 0 29 
14 Paranoid 25 M 18 0.7 Thiolhixene 400 4 25 
Means 3 I. i 13.6 7.7 654.0 ! .9 24.4 
a positive-symptom score from the BPRS (Hedlund and Vieweg 1980), consisting of the 
summed scores for thought disorganization, suspiciousness, hallucinatory behavior, and 
unusual thought content. 
On the days when the patients underwent sleep studies, daytime napping was not 
permitted. Polysomnography was performed while the patients slept in their own hos- 
pital beds, with the data transmitted via a multiplexing system (Telefactor Corp., West 
Conschocken, PA) to a nearby sleep laboratory control room and recorded on a Grass 
Model 78B polygraph with band pass settings from 0.5 to 30 Hz. The first night of 
recording involved a full montage PSG, including EEG (C3/A2), electrooculogram 
(EOG), submental electrc,nyogram (EMG), respiratory monitoring, electrocardiogram 
(ECG), and EMG of the arl~erior tibialis muscle (to assess periodic leg movements). 
The first night was used to exclude any primary sleep disorder and to acclimatize the 
subjects to the recording conditions. Data from this night were not used in the analy- 
sis. A second pretreatment PSG utilized only EEG, EOG, and EMG for sleep-staging. 
The sleep study performed after initiation of neuroleptic therapy assessed sleep staging 
only. Subjects underwent two nights of sleep recording on neuroleptic medication that 
were averaged for data analysis, except for three patients in whom only one night was 
available. 
Trained raters, blind to diagnosis and medication status, scored the sleep records 
according to modified Rechtschaffen-Kales criteria (1968). The following sleep continuity 
measures were assessed: net total time spent asleep (TSA), sleep latency (SL--time 
between lights out and first l0 min of stage 2,3, or 4 sleep not intetrul~ed by more than 
2 min of stage l or 1 rain of stage i plus ! rain of waking), arousals to wakefulness, 
time awake after the onset of sleep (wakefulness), sleep efficiency (TSAJtotal recording 
period), and sleep maintenance (TSA/SL-total recording). REM latency was taken as the 
time from sleep onset until the onset of the first REM period 3 min or more in duration, 
minus intervening time awake (RLMA). Other REM measures include REM activity (sum 
of visually scored eye-movement density from each 6-see REM epoch on a 0-8 scalo), 
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Table 2. Sleep Parameters Before and After Neurolephc Treatment (14 Patiem-Nights f:~r 
Pretreatment PSG and 25 Patient-Nights for Posttreatmem PSG) 
Pretreatment Posttreatment 
mean = SD mean *_ SD 
Sleep continuity 
Sleep latency (mint  65.8 ___ 45.8 46.0 _ 33.9" 
Total time asleep (mini  304.9 ~_ 75.0 340.2 ~ 75.6 
Awake  after sleep onset (min) 24.1 ___ 25.2 19.8 = 22.0 
Arousals 5.6 _ 3.1 5.1 " 3.4 
Sleep efficiency (%) 74.7 ~ 15.8 82.7 ~ 8.3 ° 
Sleep maintenance (,~) 9 2 2  ~ 9.1 95 0 .-r_ 5 3  
Sleep architecture 
Slage 1 %  14.8 -'_ 6 9  1 5 5  -'- 12.1 
State 2 c~ 5-1.7 ~ 9.~ 54.6 _~ 13.1 
Stage 3 % 3.9 ~ 4.7 5.0 x 4.4 
Stage 4 c~ ,t.9 +__ 9.9 6.3 -+ 10.9 
DeltaC/c ~;.8 ~ 11.4 1 1 3  ~ 13.7 
REM ck 21.7 -'- 6.1 18.7 -'- 6.3 
REM sleep 
REM latency, minus J ~ a ke  minu'es  39.4 '-  42.3 72.9 _- 51.8: 
REM periods 3.4 ' 1.3 3.1 ' -  1.0 
Total REM time (rain) 67.1 __. 28.7 65 .6  ~ 28.0 
Total REM activity 79.5 ~ 59.6 88.5 -* 65.3 
Totai REM density I. I I '-  0.32 1 2 4  .-': (I 52 
First REM period 
T i m e l m i n )  11.8 *__ 7.6 18.4 = 12.5 
Activity 12.6 '" 8.0 24.5 ~ 23.4 
Density 1.06 -L-_ 0.48 1.14 --L- 0 .59 
up < 005  by paired t-test 
total REM time, and REM densit), (REM activity/REM time) We examined these REM 
measures for the entire night and for the first REM pe, riod. Sleep architecture was des- 
ignated as stages i.  2, 3, and 4, and analyzed principally as a percentage of TSA. Delta 
percentage was the sum of stages 3 and 4, taken as a percentage of TSA. 
The PSG variables frequently exhibited nonparametric distributions, so we utilized 
nonparametric statistics (Wilcoxon signed rank test and Spearman rank correlation) as 
well as paired t-tests with appropriate data transformations to normalize the data (loga- 
rithmic, ,square root, or arcsin). Analysis of the clinical rating scales was by Student's 
,-test. 
Resul t s  
We found no difference between the first and second nights when the patients were on 
medication, so we have averaged these two nights for the analysis. Parametric and 
nonparametric tests gave virtually identical results, so we list the results of the sleep EEG 
studies on Table 2 with the results of parametric testing. The major findings were improved 
sleep continuity measures, such that the treated patients fell asleep earlier (46.0 versus 
65.8 min, p < 0.05) and had a trend towards more total sleep time (340.2 versus 304.9, 
p = 0.06),  which also appeared as greater sleep efficiency (82.7 versus 74.7, p < 0.05). 













Figure I. REM latency recorded in 14 schizophrenic patients before treatment (14 patient-nights) 
and after 3 weeks of neuroleptic therapy (25 patient-nights). 
However, their sleep still appeared relatively fragmented, with no change in arousals, 
time awake after sleep onset, or sleep maintenance. Sleep architecture showed no changes 
with treatment. 
Measures of REM sleep exhibited an increase in REM latency from 39.4 to 72.9 min 
(p < 0.05), although 7 of the 14 patients still had REM latencies less than 60 min (Figure 
i). Other REM measures did not show significant changes. 
The clinical ratings showed a significant improvement, with total BPRS decreasing 
from 47.6 _+ 12.3 (SD) to 32.4 _+ 6. i (df = 13, t = 6.03, p < 0.0001), BPRS positive 
symptoms decreasing from 14.8 ~ 4.1 to 9.2 ± 2.0 (dr = 13, t = 6.05, p < 0.0001) 
and SANS scores going from 12.4 -+ 5.1 to7.9  - 4.2 (df = 13, t = 6 .12 ,p  < 0.0001). 
Figure 2 displays scattergrams of the BPRS scores both before and on neuroleptics, 
demonstrating that except for three subjects, all subjects showed a decrease in symptom 
severity of at least I0 points. 
In order to minimize the effects of outlicrs (persisting even after data transformation), 
we used Spearman rank correlations to correlate sleep variables with clinical rating scales. 
Table 3 lists the correlations at the p < 0.05 level plus several other PSG variables of 
interest. The positive symptom subscale of the BPRS paralleled the total BPRS scores, 
so only total scores appear in Table 3. Because of the number of statistical terns p,~dormed, 
we have taken as significant only those comparisons at the p < 0.01 levc KEM latency 
in the pretreatment PSG exhibited very strong negative correlations with ,:~'h negative 
symptoms and total BPRS ~ores. However, this polysornnogram variable measured after 
3 weeks of neuroleptic treatment did not exhibit any significant correlations with clinical 
ratings measured after 3 weeks of treatment. Fisher z-transformations of the Spearman 
rank correlation coefficients (Zar 1984) for REM latency with BPRS and SANS scores 
revealed a significant change in these associations with neuroleptic therapy. 
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Figure 2. Brief psychiatric rating 
scale (BPRS) total scores for 14 
patients at baseline and after an 
average of 24.4 days of neuro- 
leptic treatmcht. 
Discussion 
In this group of 14 schizophrenic patients treated with clinically indicated doses of 
neuroleptics, polysonmographic findings after approximately 3 weeks of treatment showed 
decreased sleep latency, improved sleep efficiency, and increased REM latency. Signif- 
icant changes in sleep architecture were not evident in this sample. 
Our findings of improved sleep continuity measures with neuroleptic treatment confirms 
previous reports in the literature (Jus ct al 1968; Kaplan et al 1974; Gillin et al 1977, 
1978; Keshavan et al 1989). Comparison between the improved sleep efficiency and 
shortened sleep latency in our patients with published values of normal subjects, as well 
as normal controls of similar ages from our database (Tandon et al 1991), suggest that 
Table 3. Spearman Rank Correlations (r,) Between PSG Variables and Clinical Ratings 
Clinical Ratings 
~ n t  On .eurole~cs 
PSG variable SANS BPRS SANS BPRS 
Wake fu lness  - O. 23 - O. 30  - 0 .01 - O. 19 
Sleep la tency  O. 20 O. 24 - O. 2.5 - 0 . 2 2  
Stage ! % -0 .67  -0 .35  -0 .10  0,05 
Delta % 0.34 0.16 0.47 0.30 
R~M latency -0 .72  ~ - 0 . 7 ~  -0 .35 '  - 0 . 3 V  
Total REM activity 0.40 0.35 0.36 0.39 
REM % 0.59 0.58 0.29 0.32 
°Sigmfic~ of r, v~dues: p < 0.01. 
bS;~nlfic~nce o{ r, vaJuL.s: p < 0.005 
'Signific~lc~ of dumge of r0 values with lw.aurlem: p < 0.01. 
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although these measures improve, they do not return to normal values after 3 weeks of 
treatment. Longer-term studies are required to assess whether these measures return to 
normal. 
Poor sleep continuity is nonspecific and exists in many other psychiatric disorders, 
such as depression (Reynolds and Kupfer 1987), generalized anxiety disorders (Reynolds 
et al 1983), and obsessive-compulsive disorder (lnsel et al 1982). At the most general 
level, the improvement in sleep may reflect a lessening of the "stress" of being in the 
acute phases of psychosis and hospitalization. Another possibility is that a direct medi- 
cation effect, unrelated to pathophysiology, caused the improved sleep efficiency. This 
has not been reported in normals after acute administration of neuroleptics (Sagales and 
Erill 1975: Adam et al 1976), but the more restricted range of sleep efficiencies and a 
ceiling effect in normais might mask such a finding. Both haloperidoi and thiothixene 
have lt~-histaminergic antagonism, which is associated with increased sleep efficiency 
(Monti et al 1985). Even though disturbed sleep efficiency occurs in other disorders, it 
could still result from pathophysiological mechanisms hypothesized to underlie schizo- 
phrenia. Poor sleep efficiency has been found after the administration ofdopamin,-, agonists 
(Cianchetti 1985; Nicholson et al 1989), consistent with the increased dopaminergic 
activity hypothesized to occur in schizophrenia, and after the administration of cholin- 
esterase inhibitors (Sitaram et al 1977), consistent with the increased cholinergic activity 
also hypothesized :o occur in schizophrenic (Tandon and Greden 1989). Further studies 
are necessary to distinguish between these hypotheses. 
Although the mean and median REM latency of our schizophrenic patients increased, 
one half of our subjects continued to demonstrate latencies shorter than 60 min. Several 
interpretations of this finding may be offered. Because sleep latency was also decreased, 
it is possible that the first REM period occurred at the same clock time in ooth pretreatment 
and posttreatment conditions. The presence of two different neuroleptics confounds inte_."- 
pretations of the findings, as well as the fact that ten of the subjects received anticholinergic 
medication--all of the nine patients taking thiothixene and only one of the five patients 
taking haloperidol. The patients receiving anticholinergics had longer REM latencies than 
those not receiving them. Cholinergic antagonists tend to delay the onset of REM sleep 
in normals, although this effect may diminish with repeated administration (Sagales et 
al 1976: Gillin et ai 1989). Whe, we separately considered those patients receiving 
halopefidol, we did not find a significant increase in REM latency. This agrees with 
previous reports (ltil et al 1970; Keshavan et al 1989), but our small number of subjects 
on haloperidol requires cautious interpretation. 
The percentage of time in REM sleep showed a nonsignificant decrease with neuroleptic 
treatment. However, time spent in REM coes not maintain a consistent proportional 
relationship with total sleep time, tending to occur later in sleep (Nicholson et ai 1989). 
Given that the patients slept more with treatment, REM percent should increase slightly. 
Analysis of all REM periods did not reveal a significant difference, but a larger sample 
may be necessary to demonstrate a reduction in REM time. 
Clinical severity had a very strong correlation with shortened REM latency before 
treatment, such that shortened REM latency before treatment is associated with greater 
symptom severity as assessed by both SANS and BPRS scales. The association between 
severity and shortened REM latency has also been demonstrated in depressed patients 
(Kupfer et al 1983: Reynolds and Kupfer 1987). Such associations across patient groups 
suggest that shortened REM latency has a state component in general illness severity. 
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We do not know whether the patients with shortened REM latency would exhibit nor- 
malization after more treatment, which was found in the early studies by Kupfer et al 
(1970), or whether a traitlike measure of abnormality would persist. 
Significantly, none of the posttreatment clinical variables had any significant corre- 
lations with the posttreatment sleep study variables we examined, in spite of the fact that 
~!~cse measurements were done within 1 or 2 days of each other. A dissociation occurred 
:~etween the mechanisms that linked early REM onset with clinical severity, even though 
,~,ven of our patients continued to have abnormally short REM latencies after 3 weeks 
,i ~reatment. With the design of this study, we cannot say whether or not medication by 
~,,~clf or specific pathophysiologicai change associated with the clinical change dissociated 
~cse variables. The fact that treated patients had less range in their symptom ratings 
~ust  also be taken into account when considering this dissociation. 
We regard our findings as preliminary and in need of replication with a larger sample 
size. The fact that we tested 20 PSG variables and found 3 correlations at the p < 0.05 
level raises the possibility of  type 1 errors and requires tentative conclusions. A more 
standardized neuroleptic regimen with neuroleptic blood levels would also st~ngthen the 
significance of future findings. 
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